Elite Pharmaceuticals Files ANDA for Oxycodone Hydrochloride Extended Release -…

Elite Pharmaceuticals, Inc. announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for a generic version of OxyContin (extended release Oxycodone Hydrochloride). OxyContin is approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. 

OxyContin is formulated such that the tablets provide physical (more…)

Opioid Crisis Fast Facts – CNN

Experts say the United States is in the throes of an opioid epidemic, as more than two million of Americans have become dependent on or abused prescription pain pills and street drugs.

Opioids are drugs formulated to replicate the pain reducing properties of opium. They include both legal painkillers like morphine, oxycodone, or hydrocodone prescribed by doctors for acute or chronic pain, (more…)

Efficacy of Abuse-Deterrent Morphine, Oxycodone Assessed – Monthly Prescribing Reference…

September 08, 2017

image”>The researchers found that physical manipulation "does not defeat the ER mechanism of morphine MorphaBond ER."

The researchers found that physical manipulation “does not defeat the ER mechanism of morphine MorphaBond ER.”

The following article features coverage from PAINWeek 2017 in Las Vegas, Nevada. Click here to read more of MPR‘s conference coverage.

LAS VEGAS — Administration of abuse-deterrent formulations of immediate-release (IR) oxycodone and extended-release (ER) morphine leads to slower and lower absorption rates in (more…)